Literature DB >> 24288037

Dietary triheptanoin rescues oligodendrocyte loss, dysmyelination and motor function in the nur7 mouse model of Canavan disease.

Jeremy S Francis1, Vladimir Markov, Paola Leone.   

Abstract

The inherited pediatric leukodystrophy Canavan disease is characterized by dysmyelination and severe spongiform degeneration, and is currently refractory to treatment. A definitive understanding of core disease mechanisms is lacking, but pathology is believed to result at least in part compromised fatty acid synthesis during myelination. Recent evidence generated in an animal model suggests that the breakdown of N-acetylaspartate metabolism in CD results in a heightened coupling of fatty acid synthesis to oligodendrocyte oxidative metabolism during the early stages of myelination, thereby causing acute oxidative stress. We present here the results of a dietary intervention designed to support oxidative integrity during developmental myelination in the nur7 mouse model of Canavan disease. Provision of the odd carbon triglyceride triheptanoin to neonatal nur7 mice reduced oxidative stress, promoted long-term oligodendrocyte survival, and increased myelin in the brain. Improvements in oligodendrocyte survival and myelination were associated with a highly significant reduction in spongiform degeneration and improved motor function in triheptanoin treated mice. Initiation of triheptanoin treatment in older animals resulted in markedly more modest effects on these same pathological indices, indicating a window of therapeutic intervention that corresponds with developmental myelination. These results support the targeting of oxidative integrity at early stages of Canavan disease, and provide a foundation for the clinical development of a non-invasive dietary triheptanoin treatment regimen.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24288037     DOI: 10.1007/s10545-013-9663-6

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  42 in total

Review 1.  Molecular water pumps and the aetiology of Canavan disease: a case of the sorcerer's apprentice.

Authors:  M H Baslow
Journal:  J Inherit Metab Dis       Date:  1999-04       Impact factor: 4.982

2.  Accumulation of N-acetyl-L-aspartate in the brain of the tremor rat, a mutant exhibiting absence-like seizure and spongiform degeneration in the central nervous system.

Authors:  K Kitada; T Akimitsu; Y Shigematsu; A Kondo; T Maihara; N Yokoi; T Kuramoto; M Sasa; T Serikawa
Journal:  J Neurochem       Date:  2000-06       Impact factor: 5.372

Review 3.  N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction.

Authors:  J B Clark
Journal:  Dev Neurosci       Date:  1998       Impact factor: 2.984

4.  Astrocyte-neuron lactate transport is required for long-term memory formation.

Authors:  Akinobu Suzuki; Sarah A Stern; Ozlem Bozdagi; George W Huntley; Ruth H Walker; Pierre J Magistretti; Cristina M Alberini
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

5.  N-Acetylaspartate reduction as a measure of injury severity and mitochondrial dysfunction following diffuse traumatic brain injury.

Authors:  S Signoretti; A Marmarou; B Tavazzi; G Lazzarino; A Beaumont; R Vagnozzi
Journal:  J Neurotrauma       Date:  2001-10       Impact factor: 5.269

Review 6.  Functions of N-acetyl-L-aspartate and N-acetyl-L-aspartylglutamate in the vertebrate brain: role in glial cell-specific signaling.

Authors:  M H Baslow
Journal:  J Neurochem       Date:  2000-08       Impact factor: 5.372

7.  Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.

Authors:  Maria Traka; Robert L Wollmann; Sonia R Cerda; Jason Dugas; Ben A Barres; Brian Popko
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

8.  Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease.

Authors:  R Kaul; G P Gao; K Balamurugan; R Matalon
Journal:  Nat Genet       Date:  1993-10       Impact factor: 38.330

9.  Glyceryl triacetate for Canavan disease: a low-dose trial in infants and evaluation of a higher dose for toxicity in the tremor rat model.

Authors:  C N Madhavarao; P Arun; Y Anikster; S R Mog; O Staretz-Chacham; J R Moffett; N E Grunberg; W A Gahl; A M A Namboodiri
Journal:  J Inherit Metab Dis       Date:  2009-08-15       Impact factor: 4.982

10.  Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease.

Authors:  Mitra Assadi; Christopher Janson; Dah-Jyuu Wang; Olga Goldfarb; Neeti Suri; Larissa Bilaniuk; Paola Leone
Journal:  Eur J Paediatr Neurol       Date:  2010-01-19       Impact factor: 3.140

View more
  14 in total

Review 1.  Clinical applications involving CNS gene transfer.

Authors:  Boris Kantor; Thomas McCown; Paola Leone; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

2.  Making the White Matter Matters: Progress in Understanding Canavan's Disease and Therapeutic Interventions Through Eight Decades.

Authors:  Seemin S Ahmed; Guangping Gao
Journal:  JIMD Rep       Date:  2015-01-21

3.  An Altered Sphingolipid Profile as a Risk Factor for Progressive Neurodegeneration in Long-Chain 3-Hydroxyacyl-CoA Deficiency (LCHADD).

Authors:  Sara Tucci
Journal:  Int J Mol Sci       Date:  2022-06-27       Impact factor: 6.208

Review 4.  Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Authors:  Dominic J Gessler; Guangping Gao
Journal:  Methods Mol Biol       Date:  2016

5.  White matter apoptosis is increased by delayed hypothermia and rewarming in a neonatal piglet model of hypoxic ischemic encephalopathy.

Authors:  B Wang; J S Armstrong; M Reyes; E Kulikowicz; J-H Lee; D Spicer; U Bhalala; Z-J Yang; R C Koehler; L J Martin; J K Lee
Journal:  Neuroscience       Date:  2015-12-29       Impact factor: 3.590

6.  Atypical clinical and radiological course of a patient with Canavan disease.

Authors:  Catherine Sarret; Odile Boespflug-Tanguy; Diana Rodriguez
Journal:  Metab Brain Dis       Date:  2015-11-19       Impact factor: 3.584

7.  N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.

Authors:  Jeremy S Francis; Ireneusz Wojtas; Vladimir Markov; Steven J Gray; Thomas J McCown; R Jude Samulski; Larissa T Bilaniuk; Dah-Jyuu Wang; Darryl C De Vivo; Christopher G Janson; Paola Leone
Journal:  Neurobiol Dis       Date:  2016-10-04       Impact factor: 5.996

Review 8.  Metabolic Dysfunctions in Amyotrophic Lateral Sclerosis Pathogenesis and Potential Metabolic Treatments.

Authors:  Tesfaye W Tefera; Karin Borges
Journal:  Front Neurosci       Date:  2017-01-10       Impact factor: 4.677

9.  Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency.

Authors:  Fanny Mochel; Elodie Hainque; Domitille Gras; Isaac M Adanyeguh; Samantha Caillet; Bénédicte Héron; Agathe Roubertie; Elsa Kaphan; Romain Valabregue; Daisy Rinaldi; Sandrine Vuillaumier; Raphael Schiffmann; Chris Ottolenghi; Jean-Yves Hogrel; Laurent Servais; Emmanuel Roze
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-11-03       Impact factor: 10.154

10.  Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Tesfaye W Tefera; Yide Wong; Mallory E Barkl-Luke; Shyuan T Ngo; Nicola K Thomas; Tanya S McDonald; Karin Borges
Journal:  PLoS One       Date:  2016-08-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.